目的 本研究旨在探讨组织蛋白酶A(cathepsin A,CTSA)在肝细胞癌(hepatocellular carcinoma,HCC)中的表达特征及其对肿瘤细胞生长的影响,并分析其与B细胞淋巴瘤-2蛋白(B-cell lymphoma 2,BCL-2)稳定性的关系。方法 基于癌症基因组图谱(the cancer genome atlas,TCGA)数据库分析CTSA在HCC组织中的表达及其与临床特征/预后的关系;采用实时荧光定量PCR(quantitative real-time PCR,qRT-PCR)及免疫组织化学(immunohistochemistry,IHC)检测CTSA在HCC组织及细胞中的表达。在Huh7与HepG2细胞中构建CTSA敲低模型,通过细胞计数试剂盒-8(cell counting kit-8,CCK-8)与克隆形成实验评估细胞增殖能力,并采用流式细胞术检测凋亡水平;建立裸鼠皮下移植瘤模型验证体内成瘤能力。通过免疫共沉淀检测CTSA与BCL-2的相互作用,并采用环己酰亚胺(cycloheximide,CHX)追踪实验结合蛋白定量分析BCL-2的降解动态。结果 数据库分析及实验检测显示,CTSA在HCC中表达上调。CTSA敲低可抑制HCC细胞增殖、降低克隆形成能力并促进细胞凋亡(流式细胞术显示凋亡率由4.2%升至14.7%);在裸鼠皮下移植瘤模型中,CTSA敲低组肿瘤体积与重量均降低。机制研究表明,CTSA可与BCL-2发生相互作用并影响其蛋白稳定性,进而调控BCL-2相关抗凋亡过程。结论 本研究表明CTSA在HCC中高表达并与不良预后相关,敲低CTSA可抑制肝癌细胞增殖并促进凋亡。机制上,CTSA通过稳定BCL-2蛋白维持抗凋亡信号,从而促进肿瘤生长。
Abstract
Objective To investigate the expression characteristics of cathepsin A (CTSA) in hepatocellular carcinoma (HCC), its effects on tumor cell growth, and its association with BCL-2 protein stability. Methods CTSA expression in HCC and its relationship with clinicopathological features/prognosis were analyzed using The Cancer Genome Atlas (TCGA) dataset. CTSA expression in HCC tissues and cells was examined by quantitative real-time PCR (qRT-PCR) and immunohistochemistry (IHC). CTSA knockdown was performed in Huh7 and HepG2 cells. Cell proliferation was assessed by Cell Counting Kit-8 (CCK-8) and colony formation assays, and apoptosis was evaluated by flow cytometry. A subcutaneous xenograft model was established to validate the in vivo effect. Co-immunoprecipitation was used to determine the interaction between CTSA and BCL-2. Cycloheximide (CHX) chase combined with protein quantification was conducted to assess BCL-2 degradation dynamics. Results Database analysis and experimental validation showed that CTSA was upregulated in HCC. CTSA knockdown inhibited HCC cell proliferation, reduced clonogenic capacity, and promoted apoptosis (flow cytometry showed an increase in apoptosis rate from 4.2% to 14.7%). In the subcutaneous xenograft model, tumor volume and weight were reduced in the CTSA knockdown group. Mechanistically, CTSA interacted with BCL-2 and affected its protein stability, thereby regulating BCL-2-related anti-apoptotic processes. Conclusion Our study shows that CTSA is highly expressed in HCC and correlates with poor prognosis. CTSA knockdown inhibits hepatocellular carcinoma cell proliferation and promotes apoptosis, partly by stabilizing BCL-2 and maintaining anti-apoptotic signaling.
关键词
组织蛋白酶A /
肝细胞癌 /
细胞增殖 /
BCL-2 /
蛋白稳定性
Key words
cathepsin A /
hepatocellular carcinoma /
cell proliferation /
BCL-2 /
protein stability
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] SIEGEL RL, GIAQUINTO AN, JEMAL A.Cancer statistics, 2024[J]. CA Cancer J Clin, 2024, 74(1): 12-49.
[2] GILLES H, GARBUTT T, LANDRUM J.Hepatocellular carcinoma[J]. Crit Care Nurs Clin North Am, 2022, 34(3): 289-301.
[3] ZAMYATNIN AA, GREGORY LC, TOWNSEND PA, et al.Beyond basic research: the contribution of cathepsin B to cancer development, diagnosis and therapy[J]. Expert Opin Ther Targets, 2022, 26(11): 963-977.
[4] ERIKSSON I, ÖLLINGER K.Lysosomes in cancer-at the Crossroad of good and evil[J]. Cells, 2024, 13(5): 459.
[5] 吴洁, 张婷婷, 李珂. 组织蛋白酶A维持肿瘤干细胞性状促进三阴性乳腺癌发生发展[J]. 药学学报, 2024, 59(7): 2020-2029.
[6] WANG H, XU F, YANG F, et al.Prognostic significance and oncogene function of cathepsin A in hepatocellular carcinoma[J]. Sci Rep, 2021, 11(1): 14611.
[7] VOGLER M, BRAUN Y, SMITH VM, et al.The BCL2 family: from apoptosis mechanisms to new advances in targeted therapy[J]. Signal Transduct Target Ther, 2025, 10(1): 91.
[8] KALONI D, DIEPSTRATEN ST, STRASSER A, et al.BCL-2 protein family: attractive targets for cancer therapy[J]. Apoptosis, 2023, 28(1-2): 20-38.
[9] XU J, DONG X, HUANG DCS, et al.Current advances and future strategies for BCL-2 inhibitors: potent weapons against cancers[J]. Cancers, 2023, 15(20): 4957.
[10] TANG GLQ, LAI JXH, PERVAIZ S.Ubiquitin-proteasome pathway-mediated regulation of the Bcl-2 family: effects and therapeutic approaches[J]. Haematologica, 2024, 109(1): 33-43.
[11] TOSS MS, MILIGY IM, HAJ-AHMAD R, et al.The prognostic significance of lysosomal protective protein (cathepsin A) in breast ductal carcinoma in situ[J]. Histopathol, 2019, 74(7): 1025-1035.
[12] HU B, ZHU X, LU J.Cathepsin A knockdown decreases the proliferation and invasion of A549 lung adenocarcinoma cells[J]. Mol Med Rep, 2020, 21(6): 2553-2559.
[13] NI S, WENG W, XU M, et al.Mir-106b-5p inhibits the invasion and metastasis of colorectal cancer by targeting CTSA[J]. Onco Targets Ther, 2018, 11: 3835-3845.
[14] PALABIYIK AA.The role of Bcl-2 in controlling the transition between autophagy and apoptosis[J]. Mol Med Rep, 2025, 32(1): 172.
[15] PEMBERTON JM, POGMORE JP, ANDREWS DW.Neuronal cell life, death, and axonal degeneration as regulated by the BCL-2 family proteins[J]. Cell Death Differ, 2021, 28(1): 108-122.
[16] VAFA A, RAIS B, AFROZ N, et al.The BCL-2-tumor microenvironment axis: mechanisms of immune suppression, resistance, and pathways to therapeutic reprogramming[J]. Crit Rev Oncol Hematol, 2026, 217: 105005.
基金
国家自然科学基金面上项目“基于单细胞测序技术的ALD相关肝巨噬细胞亚群动态监测与功能研究”(82170607); 湖南省自然科学基金杰出青年基金“免疫微环境与酒精性肝病”(2022JJ10037); 湖南省大学生研究性学习和创新性实验计划项目“肝细胞SIRT7介导的肝肠轴调控在酒精性肝病中的作用机制研究”(S202510542440)